Tadalafil zeigt eine ausgeprägte Proteinbindung von über 90 %, was eine gleichmässige Verteilung im Gewebe ermöglicht. Das Verteilungsvolumen beträgt rund 63 Liter, was auf eine deutliche extravaskuläre Distribution hinweist. Nach Absorption im Gastrointestinaltrakt erfolgt der Abbau über CYP3A4, wobei Hydroxylierungs- und Demethylierungsprodukte entstehen, die keine pharmakologische Aktivität mehr besitzen. Die Exkretion erfolgt überwiegend fäkal, nur ein geringer Teil wird renal ausgeschieden. Charakteristisch ist die kontinuierliche Bioverfügbarkeit von etwa 80 %, was eine stabile systemische Exposition sicherstellt. Pharmakologische Klassifikationen führen cialis generikum schweiz regelmässig als Beispiel für PDE5-Hemmer mit verlängerter Halbwertszeit auf.

Microsoft word - 2010 step therapy requirements.doc

2010 Step Therapy Criteria
Effective January 1, 2010
Step Therapy Group Description Step Therapy Criteria
Requires member has filled at least a 60-day supply of a step 1 drug (i.e. long-acting beta agonist, Spiriva or inhaled corticosteroid) in the last 120 days before Advair will be covered
Requires member must have a documented 60-day trial
of either Antabuse or naltrexone before Campral will
be covered
Requires patient has tried and failed at least a 30 day
trial on step 1 drug (i.e. fexofenadine, fluticasone nasal,
Astelin or Astepro) within the last 120 days before
Clarinex, Clarinex D, Patanase or Singulair will be
Requires patient have a prescription history demonstrating at least a six week trial each of at least two preferred step 1 drugs (i.e. citalopram, fluoxetine, bupropion, sertraline, paroxetine, fluvoxamine or venlafaxine) before non-preferred agent will be covered Requires patient has a prescription history demonstrating trial of risperdal and Seroquel before step Requires member must have filled a 30-day supply of lamotrigine, valproate, topiramate or Felbatol in the last Requires member has filled a prescription for at least 2 preferred generic antibiotics in the last 30-days Requires member has filled at least two prescriptions for step one drugs (i.e. generic equivalents) in the last 180 Requires patient has filled a prescription for generic hydrocodone/APAP or hydrocodone/IBU in the last 120-days Requires member has filled a prescription for a macrolide in the last 30-days Requires member hs filled a prescription for at least two non-COX 2 selective NSAIDs in the last 120-days Requires member has flled a prescription for a sulfonylurea, metformin (or combo agent), Actos, ActoPlus Met, or Duetact within the last 120-days Requires member has filled a prescription for morphine sulfate sustained-release or Opana ER in the last 120- 2010 Step Therapy Criteria
Effective January 1, 2010
Requires member has filled a prescription for a protease-inhibitor, NRTI or NNRTI in the last 180-days Requires member has filled a prescription for preferred PPI agent(s) in the last 150-days Requires member has filled a prescription for zolpidem before Lunesta or Rozerem will be covered
Requires member has filled a prescription for a long-
acting stimulant and a short-acting stimulant within the
last 120-days Requires member has filled at least a 60-day supply of a step 1 drug (i.e. long-acting beta agonist, Spiriva or inhaled corticosteroid) in the last 120 days before Symbicort will be covered Requires member has filled a prescription for a mealtime insulin in the last 120-days, and continues to file meal-time insulin while on Symlin Member has filled a prescription for Vectical ointment in the previous 120-days Requires member has filled 2 consecutive months of allopurinol at maximum dose of 600mg per day Requires member has filled a prescription for

Source: http://www.healthplanofnevada.com/documents/2010%20Step%20Therapy%20Requirements.pdf